

#244

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Wednesday, August 19, 2026 9:50:27 AM
Last Modified: Wednesday, August 19, 2026 9:53:10 AM
Time Spent: 00:02:43
IP Address: 108.7.77.124

Page 2: Part 1

Q1

Title of activity

Symposium speaker

Q2

Date of activity

October 15, 2026

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Academic Practice

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s) Sanofi, Astrazeneca, Eli Lilly
(separate with commas)

Description of relationship(s) Membership on advisory boards

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Sanofi, Astrazeneca, Eli Lilly

Description of relationship(s)

Membership on advisory boards

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Sanofi

Description of relationship(s)

Receipt of scientific grant funding

Q9

Patents on a drug, product or device

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s)
(separate with commas)

NA

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s)
(separate with commas)

NA

Page 3: Part 2: To be completed by presenters only

Q11

No

I intend to use trade names during my presentation. Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

Q12

No

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation.

Q13**N/A**

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

Q14**Yes**

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15**Yes**

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Tanya

Q17

Last Name:

Laidlaw

Q18**She/Her**

Gender Pronouns - How would you like us to address you?

Q19

I confirm that the above information is accurate and complete.

Please review and check the items below.
